Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | RGS12 | O14924 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765055 | 1.00 | MEP1B (0.43) | MEP1BCA12CA1CA2CA7 | |
| SCHEMBL27125027 | 1.00 | MEP1B (0.43) | MEP1BCA12CA1CA2CA7 | |
| SCHEMBL22113081 | 0.84 | NLRP3 (0.45) | OPRK1KMT2AALDH1A1MEN1HIF1A | |
| SCHEMBL2586006 | 0.84 | NLRP3 (0.45) | OPRK1KMT2AALDH1A1MEN1HIF1A | |
| SCHEMBL2502292 | 0.84 | NLRP3 (0.45) | OPRK1KMT2AALDH1A1MEN1HIF1A | |
| SCHEMBL29478100 | 0.84 | NLRP3 (0.45) | OPRK1KMT2AALDH1A1MEN1HIF1A | |
| SCHEMBL27168302 | 0.84 | ALDH1A1 (0.40) | OPRK1KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL24260863 | 0.84 | MEP1B (0.47) | MEP1BCA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL3999288 | 0.83 | NLRP3 (0.44) | OPRK1KMT2AALDH1A1MEN1LMNA | |
| Hydrochloric Acid SCHEMBL30655761 | 0.83 | NLRP3 (0.44) | OPRK1KMT2AALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107090476-B | Sanglifehrin derivatives and process for preparing the same | 爱博利瓦有限公司 | 2021-09-24 | — | — | CN | disclosed |
| EP-3427737-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | NeuroVive Pharmaceutical AB (SE) | 2019-01-16 | — | — | EP | disclosed |
| EP-2654753-B1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2018-10-31 | — | — | EP | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | Neurovive Pharmaceuticals AB (SE) | 2014-03-20 | — | — | US | disclosed |
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | Neurovive Pharmaceuticals AB (SE) | 2014-03-20 | — | — | US | disclosed |
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | Neurovive Pharmaceuticals AB (SE) | 2014-03-20 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012131377-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012085553-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | MAVS, HDGF, TTPA | MEP1B 1272/4885CA12 4738/4885CA1 4884/4885 |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | HAVCR2, RPL35, CD4 | MEP1B 820/4885CA12 815/4885CA1 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.